Response to GSK Biologicals’ Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m - Related Studies

Response to GSK Biologicals’ Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m

This study has been completed.

Study NCT00136604. Last updated on June 12, 2007. Information provided by GlaxoSmithKline

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Diphtheria
		Tetanus
		Pertussis
		Hepatitis B
		Haemophilus Infections
		Meningococcal Infections

2	Additional conditions recognized in this trial
		Communicable Diseases
		Hepatitis
		Infection
		Whooping Cough

3	More general conditions related to this trial
		Actinomycetales Infections
		Bacterial Infections
		Bordetella Infections
		Corynebacterium Infections
		Digestive System Diseases
		DNA Virus Infections
		Gram-Negative Bacterial Infections
		Gram-Positive Bacterial Infections
		Hepadnaviridae Infections
		Hepatitis, Viral, Human
		Liver Diseases
		Neisseriaceae Infections
		Pasteurellaceae Infections
		Respiratory Tract Diseases
		Respiratory Tract Infections
		Virus Diseases

4	Sponsors listed in this trial
		GlaxoSmithKline